A unique Novo Nordisk legal challenge to the Medicare drug pricing program could have big implications for the pharma ...

Shares of Novo Nordisk ended higher on Monday and extended gains in after-hours trading, while "Big Pharma" rival Eli Lilly fell nearly 2% and continued slipping after the closing bell. The diverging ...

When should six drugs count as one? That question is at the heart of an unusual challenge that the pharma company Novo Nordisk is pursuing against the federal government. And the answer could have ...

The Centers for Medicare & Medicaid Services said on Friday it did not move forward with a proposal put forth by the Biden ...

Medicare Advantage updates while halting proposed anti-obesity drug coverage, impacting millions of potential beneficiaries.

The FDA had rejected the companies’ initial application in 2023, requesting additional data after the pharma firms reported ...

PITTSBURGH (CN) — Bashing a Biden-era law that gives Medicare the power to directly negotiate the price of certain high-cost prescription drugs, an attorney for the pharmaceutical giant Novo Nordisk ...

Furthermore, Novo Nordisk should earn important label expansions for some of its current medicines while developing new ones in other areas. Semaglutide is being tested in Alzheimer's disease. And the ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Novo Nordisk (NVO), which develops weight-loss drugs, looks poised to perform well over the short term, Rebecca Walser, the ...

Almost unarguably, the most significant story in our time with the pharmaceutical industry is the emergence and sharp rise of GLP-1 obesity drugs. Front and center of this is Novo Nordisk (NYSE: NVO), ...

Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...